Table 3. Overall and progression-free survival according to tumor factors in subgroups.
Population |
Median OS (95% CI) (months)
|
Hazard Ratio (95% CI) for S-LRTs (vs. S-M) | P | ||
---|---|---|---|---|---|
S-M | S-LRTs | ||||
Entire cohort | 5.5 (4.7–6.2) | 8.5 (6.2–10.7) | 0.5 (0.4–0.7) | 0.001 | |
Subgroup with neither EHS nor RNI | 7.8 (6.2–9.3) | 18.0 (3.7–33.2) | 0.4 (0.2–0.9) | 0.019 | |
Subgroup with EHS and/or RNI | 4.8 (3.7–5.8) | 8.3 (5.0–11.5) | 0.6 (0.4–0.9) | 0.028 | |
Subgroup with AFP <400 ng/mL | 7.8 (6.6–8.9) | 8.3 (5.2–11.3) | 0.8 (0.5–1.3) | 0.449 | |
Subgroup with AFP ≥400 ng/mL | 3.4 (2.5–4.2) | 8.0 (0.0–19.0) | 0.3 (0.1–0.6) | 0.001 | |
Population |
Median PFS (95% CI) (months)
|
Hazard Ratio (95% CI) for S-LRTs (vs. S-M) | P | ||
S-M | S-LRTs | ||||
Entire cohort | 3.0 (2.7–3.2) | 5.3 (4.0–6.5) | 0.6 (0.4–0.8) | 0.002 | |
Subgroup with neither EHS nor RNI | 3.2 (1.8–4.5) | 9.6 (3.1–16.0) | 0.5 (0.2–0.9) | 0.027 | |
Subgroup with EHS and/or RNI | 2.9 (2.5–3.2) | 4.9 (4.0–5.7) | 0.7 (0.4–1.0) | 0.069 | |
Subgroup with AFP <400 ng/mL | 4.0 (2.6–5.3) | 6.8 (4.1–9.4) | 0.7 (0.4–1.1) | 0.225 | |
Subgroup with AFP ≥400 ng/mL | 2.0 (1.6–2.3) | 4.2 (2.6–5.7) | 0.5 (0.3–0.8) | 0.012 |
Abbreviations: OS, overall survival; PFS, progression-free survival; CI, confidence interval; S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional treatments; EHS, extrahepatic spread; RNI, regional nodal involvement.